OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company specializing in preparations for medical use, disclosed in a recent filing that its Chief Accounting Officer, Anthony J. Krick, has sold a portion of his company stock. The transaction took place on March 18, 2024, and involved the sale of 2,345 shares at a price of $1.88 per share, resulting in a total sale value of approximately $4,408.
According to the filing, the shares sold by Krick were required to cover tax withholding obligations associated with the vesting of restricted share units under multiple award agreements. This "sell to cover" transaction is a common practice mandated by the issuer's award agreement under its equity incentive plan. It is important to note that this sale does not represent a discretionary trade by Krick.
Following the transaction, Krick still retains a significant stake in the company, owning 143,988 shares of OptiNose common stock. The sale occurred directly and was reported in compliance with SEC regulations.
OptiNose, based in Yardley, Pennsylvania, is incorporated in Delaware and operates within the pharmaceutical industry, focusing on developing innovative products to address unmet medical needs. The company's business address and mailing address are both located at 1020 Stony Hill Road, Suite 300, Yardley, PA, 19067.
InvestingPro Insights
OptiNose, Inc. (NASDAQ:OPTN) has recently been in the spotlight due to an insider stock sale by its Chief Accounting Officer. This financial move comes at a time when the company shows a mix of financial strengths and challenges. According to InvestingPro data, OptiNose boasts an impressive gross profit margin of 87.84% for the last twelve months as of Q4 2023. This indicates a strong ability to control costs relative to its revenue and could be a positive signal for investors looking at the company's operational efficiency.
However, the company's stock price performance tells a different story. InvestingPro data reveals a substantial return over the last month of 41.76%, coupled with a three-month price total return of 68.26%, and a six-month price total return of 52.36%. These figures suggest that the company's stock has been on an upward trajectory, possibly indicating investor optimism or a market response to broader company activities or industry trends.
On the flip side, two InvestingPro Tips highlight potential concerns for investors. OptiNose's stock price often moves in the opposite direction of the market, which might suggest idiosyncratic risk factors at play. Additionally, the company's short-term obligations exceed its liquid assets, which could raise questions about its financial agility in the near term. Investors interested in a deeper analysis can find more InvestingPro Tips on OptiNose by visiting Investing.com. There are a total of 9 additional tips that can provide a more comprehensive understanding of OptiNose's financial health and market position.
For those looking to make an informed decision on OptiNose, InvestingPro offers a valuable resource for in-depth financial data and analysis. As a special offer, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking even more insights to guide their investment choices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.